Summary of Loading Off Q2 > Annual Report Bottom - As At
Summary of Loading Off Q2 > Annual Report Bottom - As At Close April 20 [no change].
Bought at .0005:
January 19: 3M
January 23: 3M
Total: 6M
Bought at .0004:
August 23: 9.5M
September 1: 1.5M
September 6: 4M
September 7: 1M
September 11: 5M
September 15: 63M
September 21: 1M
September 26: 62M
September 27: 65M
September 28: 36M
September 29: 7M
October 2: 13M
October 3: 1M
October 5: 5M
October 6: 11M
October 9: 4M
October 11: 14M
October 12: 1M
October 16: 9M
October 17: 6M
October 18: 2M
October 19: 1M
October 23: 2M
October 24: 3M
October 25: 7M
October 26: 16M
October 31: 3M
November 2: 1M
November 3: 3M
November 6: 4M
November 7: 1M
November 9: 1M
November 10: 4M
November 14: 3M
November 16: 1M
November 17: 5M [discounting double print of a 2M buy]
November 20: 10M
November 21: 2M
November 22: 2M
November 24: 2M
November 27: 4M
November 28: 1M
November 30: 3M
December 5: 2M
December 12: 1M
December 14: 1M
December 28: 9M
December 29: 4M
January 3: 7M
January 5: 1M [rounded down from 1.4M]
January 8: 1M
January 11: 51M
January 19: 20M
January 24: 3M
January 29: 1M [rounded up from 684K with 500K from January 26]
January 30: 2M [rounded up from 1.7M]
February 2: 6M
February 5: 2M
February 6: 4M
February 8: 5M
February 9: 2M
February 12: 2M
February 13: 2M
February 14: 3M
February 15: 8M
February 16: 1M
March 2: 4M [rounded up]
March 5: 4M [rounded down]
March 6: 1M
March 7: 1M [rounded up]
March 8: 2M [rounded down]
March 9: 3M [rounded up]
March 12: 11M
March 13: 5M
March 22: 12M
March 23: 6M [rounded down]
March 28: 2M
Aoril 17: 1M
Total: 587M
Bought at .0003:
September 15: 1M
October 2: 3M
October 6: 3M
October 9: 7M
October 17: 1M [rounded up from 850K]
November 22: 3M
November 30: 1M
December 1: 11M
December 5: 30M
December 6: 4M [rounded down from 4.4M]
December 7: 8M
December 8: 13M
December 12: 2M
December 14: 96M
December 15: 13M
December 18: 5M
December 19: 3M
December 21: 2M
December 22: 2M
December 27: 2M
December 28: 3M
December 29: 8M
January 2: 1M [rounded down from 1.5M]
January 3: 13M
January 4: 1M [rounded up from 800K]
January 10: 1M
January 18: 13M [rounded down from 13.4M]
February 6: 1M
February 12: 3M
February 14: 1M [rounded up]
February 16: 1M
February 21: 2M [rounded down]
March 1: 1M [rounded up]
March 14: 4M
March 20: 12M [rounded down]
March 22: 5M
March 23: 7M
March 28: 4M [rounded up]
April 2: 11M [rounded up]
April 3: 10M [rounded down]
April 5: 8M [rounded down]
April 9: 3M [rounded down]
April 10: 1M [rounded down]
April 11: 5M [rounded up]
April 12: 2M
April 13: 2M [rounded up]
April 17: 13M
April 18: 3M [rounded up]
Total 351M
Bought at .0002:
April 17: 5M [rounded up]
Total: 5M [out of 138M bid]
American EcoFuels Inc (AEFI) Stock Research Links
"Per Ardua Ad Astra" - "Through Adversity To The Stars"
A very apposite motto for those who trade successfully in the OTC market..
All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Top 5 Most Recently Viewed Articles
Insights from APA Corporation's Q3 2024 Financial Update HOUSTON -- APA Corporation (Nasdaq: APA) has released key information regarding its third-quarter 2024 financial and operational results. This supplemental information serves as a guide for investors, analysts, and stakeholders to help them form their own estimates regarding the company's performance. Understanding...
Continue Reading
Insights on the US Coffee Market Growth The US coffee market is currently gearing up for an exciting decade ahead, with projections indicating it could reach USD 150.88 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.8% from 2025. This surge is largely influenced by shifting consumer preferences towards premium and specialty coffee, along with an...
Continue Reading
Understanding the Upcoming Earnings Announcement Great Lakes Dredge & Dock (NASDAQ: GLDD) is gearing up for its quarterly earnings report, and investors are eager to glean insights from the announcement. The anticipation is palpable as analysts forecast an earnings per share (EPS) of $0.09, signalling potential growth for the company. Market Reactions and Guidance It's...
Continue Reading
Calmére Estate Winery Changes Hands in Major Sale Napa Valley has long been a beacon for wine enthusiasts and savvy investors alike. The recent transaction involving Calmére Estate Winery showcases the continued potential of this iconic region. The winery, known for its exquisite Chardonnay and Pinot Noir, has been a part of the Carneros American Viticultural Area (AVA)...
Continue Reading
Mr. Splash Car Wash Takes a Strategic Step Forward Mr. Splash Car Wash, a notable name in the express car wash industry, has recently entered into a strategic partnership with NBA stars Giannis and Thanasis Antetokounmpo, along with Michael Carter-Williams. This collaboration aims to elevate the brand's presence in the Midwest, showcasing Mr. Splash's commitment to...
Continue Reading